Movement disorders reveal Creutzfeldt–Jakob disease
نویسندگان
چکیده
منابع مشابه
Movement Disorders Parkinson’s Disease
Many examples in medicine show that therapies are most effective when measurement is used to guide their implementation, dose and effects. There are effective symptomatic therapies for the motor symptoms of Parkinson’s disease, which improve quality of life and have a health economic justification for their subsidisation. As measurement should lead to more effective deployment of these therapie...
متن کاملMovement Disorders Parkinson’s Disease
Parkinson’s disease is associated with motor complications, especially dyskinesias, which limit dopaminergic replacement therapy. Safinamide is a water-soluble, orally active a-aminoamide derivative that modulates dopaminergic and glutamatergic neurotransmission with a unique dual mechanism of action. It improves motor symptoms, motor complications, quality of life and ‘on’ and ‘off’ time even ...
متن کاملMovement Disorders Parkinson’s Disease
The pathophysiology of idiopathic Parkinson’s disease (PD) is traditionally characterised as substantia nigra degeneration, but careful examination of the widespread neuropathological changes suggests individual differences in neuronal vulnerability. A major limitation to studies of disease progression in PD has been that conventional magnetic resonance imaging (MRI) techniques provide relative...
متن کاملMovement Disorders Parkinson’s Disease
Apomorphine administered subcutaneously has provided clinicians with an effective option for the rapid resolution of the symptoms of Parkinson’s disease (PD) for over a quarter of a century. It is available for use either as an intermittent injection or a continuous infusion, depending on the severity of the patient’s symptoms. This satellite symposium, held during the 18th International Congre...
متن کاملMovement Disorders Parkinson’s Disease
The emergence of the behavioral syndrome known as impulse control disorder (ICD) in Parkinson’s disease (PD) has increasingly been associated with dopamine agonist (DAA) use. Clinical reports emphasize the presence of excessive, disruptive, and ‘atypical’ behaviors in PD patients that resolve after discontinuation or reductions of DAA therapy. The severity of these behaviors has resulted in a h...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Neurology
سال: 2009
ISSN: 1759-4758,1759-4766
DOI: 10.1038/nrneurol.2009.32